Sharing Global Business Strategies for High-Dose Intravenous Iron Therapy "Ferinject"
JW Pharmaceutical announced on October 27 that it held a ceremony at its headquarters in Gwacheon, Gyeonggi Province, on the 21st to mark the 50th anniversary of its partnership with the global pharmaceutical company CSL Behring.
Shin Youngseop, CEO of JW Pharmaceutical (left), presented a plaque of appreciation to Antonio Jurdang, Global Partner Business Head at CSL Behring, on the 21st at the JW building in Gwacheon, Gyeonggi Province. JW Pharmaceutical
The ceremony was attended by Antonio Jurdang, Global Partner Business Head of CSL Behring, Patrick Pacher, Head of Asia Pacific, and Jean-Marc Morange, Senior Vice President and Head of Asia Pacific at CSL Behring.
The partnership between the two companies began in December 1975, when Daehan Jungwoo Pharmaceutical (now JW Pharmaceutical) and Hausmann Laboratories (now CSL Behring) entered into a technical collaboration for the oral iron supplement "Ferum." In 1976, the launch of Ferum in Korea provided patients and healthcare professionals with a new treatment option for iron deficiency. This was followed by additional supply agreements, leading to the domestic launch of "Venoferum" in 2005 and the high-dose intravenous iron therapy "Ferinject" in 2011.
At the ceremony, Shin Youngseop, CEO of JW Pharmaceutical, presented a plaque of appreciation to Jurdang, emphasizing that the mutual trust and shared commitment over the past half-century have expanded the horizons of iron deficiency and anemia treatment in Korea. Shin stated, "The collaboration that began with Ferum has continued with Venoferum and Ferinject, opening up new opportunities for both companies. As time has passed, this partnership has grown into a deeper and more valuable relationship. I hope our cooperation will become a global success story that contributes to better lives for patients around the world."
Jurdang commented, "JW Pharmaceutical is one of CSL Behring's longest-standing and most important partners. We are making significant efforts to develop essential therapies for patients, such as Ferinject, and I expect our partnership will continue to play a crucial role."
Prior to the plaque presentation, a special lecture was held for employees, chaired by Kim Kyunghwan, President of the Korean Patient Blood Management Society (KPBM) and Professor of Thoracic Surgery at Seoul National University Hospital. Kim Youngwoo, Professor at the National Cancer Center, gave a presentation on the status of patient blood management in Korea and the effectiveness of Ferinject for patients with acute anemia following gastrectomy. Lee Siwoon, Professor of Neurosurgery at Bundang Seoul National University Hospital, discussed the potential clinical applications of Ferinject in the treatment process for patients undergoing coil embolization for cerebral aneurysms.
After the ceremony, representatives from both companies shared updates on the status of high-dose intravenous iron therapy Ferinject in Korea and CSL's global business strategies.
JW Pharmaceutical plans to further strengthen its collaboration with CSL Behring on the occasion of the 50th anniversary of their partnership, aiming to enhance the management of iron deficiency and anemia in the Korean healthcare sector.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
